Compare Amphastar Pharmaceuticals Inc (AMPH) vs Carnival Corp (CCL) Price & Performance

AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.

The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.

Carnival (CCL) trades at $26.83, up 0.41% on the day, with a bullish fundamental recovery story supported by three consecutive quarterly EPS beats. The stock shows a bearish technical signal but strong valuation metrics including a P/E of 12.09 and ROE of 26.72%. Recent news highlights the launch of the new Carnival Destiny ship and a declared $0.15 dividend, reinforcing growth initiatives.

Outlook remains positive with analyst consensus at Buy (59.57%) and a $35 price target, though risks include geopolitical tensions impacting oil prices and European demand softness. Net income margin improved to 11.24% in 2025, with debt reduction trends supporting financial health. The stock offers upside potential if operational momentum and cost controls persist amid industry headwinds.